Prevalence of Epstein–Barr Virus Genotypes in Pakistani Lymphoma Patients

Document Type : Research Articles


1 Department of Biological Sciences, Gomal University, Dera Ismail Khan, Pakistan.

2 Princess Nourah Bint Abdulrahman University, Riyadh, Saudi Arabia.

3 Lineberger Comprehensive Cancer Center, The University of North Carolina, Chapel Hill USA, United States.

4 King Abdul Aziz University, Jeddah, Saudi Arabia.

5 Bannu Medical College, Bannu, KP, Pakistan.

6 Cornell University, Ithaca New York, United States.


The Epstein-Barr virus (EBV) is a herpesvirus infecting more than 90% of the human population. The tropism of
EBV for B lymphocytes is evidenced in its association with many lymphoproliferative disorders. Different types of EBV
(EBV-1 and EBV-2), classified on the basis of EBV nuclear antigen-2 (EBNA-2) genotyping, have been reported in
benign and malignant pathologies, but there is almost no information about their frequency in the Pakistani population.
The aim of this study was to determine the frequency and distribution of EBNA-2-based EBV genotypes in lymphoma
patients. Genomic DNA was extracted from formalin-fixed paraffin embedded (FFPE) tissue samples obtained from 73
EBV-DNA-positive lymphoma patients. The β-globin gene was amplified to assess the presence and quality of cellular
DNA from all samples. EBER-1 DNA was detected by PCR to confirm EBV presence in tissue samples. EBNA-1
mRNA relative quantification done by quantitative PCR substantiated EBNA-1 mRNA overexpression in 43.8% of
EBV-positive cases in comparison to EBV-positive control cell line. EBNA-2 genotyping was done by nested PCR.
Among typable samples, EBV-1 was found in 90.7% of samples while EBV-2 was present in 9.3% cases. These results
show that EBV-1 was the most prevalent type in the lymphoma population of Pakistan. This epidemiology of EBV in
Pakistani lymphoma patients represents an important first step in using EBV for prognosis and monitoring treatment




Main Subjects

Volume 19, Issue 11
November 2018
Pages 3153-3159
  • Receive Date: 27 February 2018
  • Revise Date: 15 August 2018
  • Accept Date: 05 October 2018
  • First Publish Date: 01 November 2018